Tag: annual report

Company Achieves Breakout Quarter as Turnaround Strategy Gains Traction; Clean-Tech Product Launches Poised to Accelerate Growth

BOCA RATON, FL, July 10, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 153,225 Solana (“SOL”) at an average purchase price of $154.85 and valued at approximately $23.72 million. Following this transaction, DeFi Dev Corp. now holds approximately 846,630 SOL and SOL equivalents, including staking rewards, making the Company the largest Solana treasury company, by both total holdings and market capitalization.

DUBLIN, July 10, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”) today announced a 1-for-35 reverse share split (the “Reverse Share Split”) of the Company’s Class A Ordinary Shares by way of a share consolidation.

FREMONT, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that production shipments of its newest electric vehicle (EV) charger, the IQ^® EV Charger 2, have expanded across Europe to now include Greece, Romania, Ireland, and Poland. The IQ EV Charger 2 is a smart charger designed to work seamlessly with Enphase solar and battery systems or as a powerful standalone charger. Additionally, in France, the IQ EV Charger 2 has received one of the country’s highest quality standards, the E.V. READY certification, and can now integrate with the “Linky” meter to enable dynamic load balancing for standalone charger installations.

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.

Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026

Aalst, Belgium, July 10, 2025 – Ontex Group NV [EURONEXT: ONTEX], a leading international developer and producer of personal care solutions, is proud to have been recognized by CDP* for the second time in a row for its climate actions in partnership with its suppliers, specifically aimed at reducing its scope 3 emissions. Ontex is among the highest-rated companies that are celebrated in the 2024 Supplier Engagement Leaderboard, which evaluates corporate supply chain engagement on climate issues. 

MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA¹ PET² imaging agent, Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System (HCPCS) code by the U.S. Centers for Medicare & Medicaid Services (CMS).

Vero Beach, Fla., July 09, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of July 2025. The dividend of $0.12 per share will be paid August 28, 2025 to holders of record of the Company’s common stock on July 31, 2025, with an ex-dividend date of July 31, 2025. The Company plans on announcing its next common stock dividend on August 13, 2025.